NOUSCOM
Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy. The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.
NOUSCOM
Industry:
Biotechnology Genetics Health Care Therapeutics
Founded:
2015-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.nouscom.com
Total Employee:
11+
Status:
Active
Contact:
+41612011831
Total Funding:
54 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics Google Tag Manager WordPress Google Universal Analytics Font Awesome Global Site Tag Mobile Non Scaleable Content
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Board_member
Current Employees Featured
Marina Udier CEO @ Nouscom
CEO
2020-02-01
Cinzia Traboni Senior Director of regulatory affairs & Co- Founder @ Nouscom
Senior Director of regulatory affairs & Co- Founder
Patricia Delaite CMO @ Nouscom
CMO
2020-02-01
Elisa Scarduelli Chief Scientific Officer & Co-Founder @ Nouscom
Chief Scientific Officer & Co-Founder
2015-06-01
Göran Ando MD & Chairman @ Nouscom
MD & Chairman
2020-12-01
Richard Davis Chief Operating Officer @ Nouscom
Chief Operating Officer
2022-05-01
Founder
Investors List
LSP BioVentures
LSP BioVentures investment in Series B - Nouscom
5AM Ventures
5AM Ventures investment in Series B - Nouscom
Versant Ventures
Versant Ventures investment in Series B - Nouscom
Abingworth
Abingworth investment in Series B - Nouscom
Life Sciences Partners
Life Sciences Partners investment in Series A - Nouscom
Versant Ventures
Versant Ventures investment in Series A - Nouscom
Key Employee Changes
Official Site Inspections
http://www.nouscom.com
- Host name: 77.209.214.35.bc.googleusercontent.com
- IP address: 35.214.209.77
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Nouscom"
Nouscom - Crunchbase Company Profile & Funding
Nouscom is a developer of an immunotherapy platform that aims to create modified viral vector vaccines for cancer treatment. The company's platform …See details»
Nouscom • History & Team
Nouscom’s leadership and research team are successful entrepreneurs, who have previously developed innovative candidate vaccines for a range of infectious diseases that include: Malaria (Ewer et al, 2013), Ebola (Stanley et al, 2014; …See details»
Nouscom - LinkedIn
Nouscom | 14,150 followers on LinkedIn. Nouscom is a private clinical stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies using proprietary viral vectors ...See details»
Nouscom - Contacts, Employees, Board Members, Advisors
Organization. Nouscom . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 9. Number of Board …See details»
Nouscom AG – Swiss Biotech
Nouscom is a privately held oncology company developing next-generation immunotherapies. Nouscom’s proprietary technology platform harnesses the full power of the immune response …See details»
Nouscom 2025 Company Profile: Valuation, Funding
Nouscom General Information Description. Developer of an immunotherapy platform designed to develop engineered viral vector vaccines for the treatment of cancer. The company's platform utilizes a portfolio of engineered viral vectors …See details»
Nouscom - Org Chart, Teams, Culture & Jobs - The Org
View Nouscom's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Nouscom Company Profile - Office Locations, Competitors ... - Craft
Nouscom develops a technology platform that is based on tumor targeted oncolytic viruses and patient-specific cancer vaccines. The Company offers Endovax antigenless vaccine that …See details»
Nouscom - Funding, Financials, Valuation & Investors - Crunchbase
Nouscom is a biotech company that develops a series of immunotherapies that are capable of selectively killing tumor cells. New. Resources. Advanced Search. ... How much funding has …See details»
NOUSCOM AG Company Profile | Basel, BASEL-STADT, Switzerland ...
Find company research, competitor information, contact details & financial data for NOUSCOM AG of Basel, BASEL-STADT. Get the latest business insights from Dun & Bradstreet.See details»
Nouscom - Products, Competitors, Financials, Employees, …
Nouscom's products include personalized and off-the-shelf cancer vaccines that target a broad range of solid tumors by harnessing the body's immune system. It was founded in 2015 and is …See details»
Nouscom Company Information - Funding, Investors, and More
Nouscom, based in Basel, has strong potential in the biotech space with its innovative viral vector-based vaccines for cancer treatment. This technology sets it apart from traditional methods …See details»
Nouscom • Cancer Genetic Vaccines and Armored Oncolytic Viruses
In March 2021, Nouscom received regulatory approval to initiate a multicenter Phase 1b trial of NOUS-PEV and will be enrolling patients in Spain and other European countries. The trial will …See details»
Nouscom Company Overview, Contact Details & Competitors
Mar 21, 2024 Nouscom hired Neil Gallagher as Independent Advisor on May 14th '24. BASEL, Switzerland - 14th May 2024 - Nouscom, a clinical stage immuno-oncology company …See details»
Nouscom - Overview, News & Similar companies | ZoomInfo.com
Who is Nouscom. Nouscom is a privately held oncology company developing next-generation immunotherapies. Nouscom's proprietary technology platform harnesses the fu ll power of the …See details»
Nouscom Raises €67.5 million ($72 million) in - GlobeNewswire
Nov 14, 2023 Nouscom Rick Davis, COO E : info@nouscom.com T : +41 61 201 1835: MEDiSTRAVA Consulting Sylvie Berrebi, Mark Swallow E : nouscom@medistrava.com T : …See details»
Nouscom Appoints Seasoned Executive Eckhard Niemeier as Chief …
BASEL, Switzerland – 3 rd December 2024 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies, …See details»
Nouscom: Patient enrollment of study for metastatic colorectal …
Nov 19, 2024 Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies, announces the completion of patient …See details»
Nouscom to Present Final Results from Successful Phase Ib/II Trial …
3 days ago Nouscom Srl . Tue, Mar 25, 2025, 4:30 PM 6 min read. Nouscom Srl. Lynch Syndrome (LS) is a common hereditary condition that significantly increases the risk of …See details»
Nouscom to Present Final Results from Successful Phase Ib/II Trial …
2 days ago Nouscom exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy developed under a multi-project agreement, which is currently under evaluation in a Phase 1 …See details»